Synapsin II is involved in the molecular pathway of lithium treatment in bipolar disorder

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Cruceanu, Cristiana ^a   Alda, Martin ^b   Grof, Paul ^c   Rouleau, Guy A ^d   Turecki, Gustavo ^a  

^a MCGILL UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Mood Disorders Centre of Ottawa   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; LITHIUM CHLORIDE; SYNAPSIN II; LITHIUM; NEUROLEPTIC AGENT; SYNAPSIN;

ADULT; AGE; AGE AT DNA SAMPLING; AGE AT FIRST TREATMENT; ALCOHOLISM; ANXIETY; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CELL LINE; CELL SPECIFICITY; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG RESPONSE; DRUG USE; EPSTEIN BARR VIRUS; FAMILY HISTORY; FEMALE; GENE; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; ONSET AGE; SCHIZOPHRENIA; SYNAPSIN II GENE; SYNAPSIN IIA GENE; SYNAPSIN IIB GENE; CELL STRAIN HEK293; CHEMISTRY; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; LYMPHOCYTE; METABOLISM; METHODOLOGY; MIDDLE AGED; NERVE CELL; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CELL LINE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HEK293 CELLS; HUMANS; LITHIUM; LYMPHOCYTES; MALE; MIDDLE AGED; NEURONS; REAL-TIME POLYMERASE CHAIN REACTION; SYNAPSINS;

EID: 84857571570     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032680     Document Type: Article

References (46)

1. Alda M, Hajek T, Calkin C, O'Donovan C, (2009) Treatment of bipolar disorder: new perspectives. Ann Med 41: 186-196.
2. Smoller JW, Finn CT, (2003) Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet 123C: 48-58.
3. Schou M, (1983) [Preventive lithium treatment in manic-depressive disease: experiences and progress in recent years]. Nervenarzt 54: 331-339.
4. Baldessarini RJ, Tondo L, (2000) Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 57: 187-190.
5. Garnham J, Munro A, Slaney C, Macdougall M, Passmore M, et al. (2007) Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord 104: 185-190.
6. Kile BM, Guillot TS, Venton BJ, Wetsel WC, Augustine GJ, et al. (2010) Synapsins differentially control dopamine and serotonin release. J Neurosci 30: 9762-9770.
7. Cesca F, Baldelli P, Valtorta F, Benfenati F, (2010) The synapsins: key actors of synapse function and plasticity. Prog Neurobiol 91: 313-348.
8. Ullrich B, Sudhof TC, (1995) Differential distributions of novel synaptotagmins: comparison to synapsins. Neuropharmacology 34: 1371-1377.
9. Haycock JW, Greengard P, Browning MD, (1988) Cholinergic regulation of protein III phosphorylation in bovine adrenal chromaffin cells. J Neurosci 8: 3233-3239.
10. Browning MD, Huang CK, Greengard P, (1987) Similarities between protein IIIa and protein IIIb, two prominent synaptic vesicle-associated phosphoproteins. J Neurosci 7: 847-853.
11. Maienschein V, Marxen M, Volknandt W, Zimmermann H, (1999) A plethora of presynaptic proteins associated with ATP-storing organelles in cultured astrocytes. Glia 26: 233-244.
12. Bhangu PS, Genever PG, Spencer GJ, Grewal TS, Skerry TM, (2001) Evidence for targeted vesicular glutamate exocytosis in osteoblasts. Bone 29: 16-23.
13. Matovcik LM, Karapetian O, Czernik AJ, Marino CR, Kinder BK, et al. (1994) Antibodies to an epitope on synapsin I detect a protein associated with the endocytic compartment in non-neuronal cells. Eur J Cell Biol 65: 327-340.
14. Bustos R, Kolen ER, Braiterman L, Baines AJ, Gorelick FS, et al. (2001) Synapsin I is expressed in epithelial cells: localization to a unique trans-Golgi compartment. J Cell Sci 114: 3695-3704.
15. Hurley SL, Brown DL, Cheetham JJ, (2004) Cytoskeletal interactions of synapsin I in non-neuronal cells. Biochem Biophys Res Commun 317: 16-23.
16. Li L, Chin LS, Shupliakov O, Brodin L, Sihra TS, et al. (1995) Impairment of synaptic vesicle clustering and of synaptic transmission, and increased seizure propensity, in synapsin I-deficient mice. Proc Natl Acad Sci U S A 92: 9235-9239.
17. Rosahl TW, Spillane D, Missler M, Herz J, Selig DK, et al. (1995) Essential functions of synapsins I and II in synaptic vesicle regulation. Nature 375: 488-493.
18. Lakhan R, Kalita J, Misra UK, Kumari R, Mittal B, Association of intronic polymorphism rs3773364 A&G in synapsin-2 gene with idiopathic epilepsy. Synapse 64: 403-408.
19. Chen Q, He G, Qin W, Chen QY, Zhao XZ, et al. (2004) Family-based association study of synapsin II and schizophrenia. Am J Hum Genet 75: 873-877.
20. Lee HJ, Song JY, Kim JW, Jin SY, Hong MS, et al. (2005) Association study of polymorphisms in synaptic vesicle-associated genes, SYN2 and CPLX2, with schizophrenia. Behav Brain Funct 1: 15.
21. Saviouk V, Moreau MP, Tereshchenko IV, Brzustowicz LM, (2007) Association of synapsin 2 with schizophrenia in families of Northern European ancestry. Schizophr Res 96: 100-111.
22. Wang Y, Yu L, Zhao T, Xu J, Liu Z, et al. (2009) No association between bipolar disorder and syngr1 or synapsin II polymorphisms in the Han Chinese population. Psychiatry Res 169: 167-168.
23. Grebb JA, Greengard P, (1990) An analysis of synapsin II, a neuronal phosphoprotein, in postmortem brain tissue from alcoholic and neuropsychiatrically ill adults and medically ill children and young adults. Arch Gen Psychiatry 47: 1149-1156.
24. Vawter MP, Thatcher L, Usen N, Hyde TM, Kleinman JE, et al. (2002) Reduction of synapsin in the hippocampus of patients with bipolar disorder and schizophrenia. Mol Psychiatry 7: 571-578.
25. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P, (2000) Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28: 53-67.
26. Lopez de Lara C, Jaitovich-Groisman I, Cruceanu C, Mamdani F, Lebel V, et al. (2010) Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses. Int J Neuropsychopharmacol 13: 1397-1410.
27. Turecki G, Grof P, Grof E, D'Souza V, Lebuis L, et al. (2001) Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry 6: 570-578.
28. Grof P, Alda M, Grof E, Zvolsky P, Walsh M, (1994) Lithium response and genetics of affective disorders. J Affect Disord 32: 85-95.
29. Sun X, Young LT, Wang JF, Grof P, Turecki G, et al. (2004) Identification of lithium-regulated genes in cultured lymphoblasts of lithium responsive subjects with bipolar disorder. Neuropsychopharmacology 29: 799-804.
30. Alda M, Keller D, Grof E, Turecki G, Cavazzoni P, et al. (2001) Is lithium response related to G(s)alpha levels in transformed lymphoblasts from subjects with bipolar disorder? J Affect Disord 65: 117-122.
31. Mamdani F, Alda M, Grof P, Young LT, Rouleau G, et al. (2008) Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B Neuropsychiatr Genet 147B: 500-504.
32. Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, et al. (2005) Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta-50 T/C SNP. Neurosci Lett 376: 51-55.
33. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
34. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
35. Chen H, Wang N, Burmeister M, McInnis MG, (2009) MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int J Neuropsychopharmacol 12: 975-981.
36. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, et al. (2009) Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34: 1395-1405.
37. Valtorta F, Benfenati F, Greengard P, (1992) Structure and function of the synapsins. J Biol Chem 267: 7195-7198.
38. De Camilli P, Benfenati F, Valtorta F, Greengard P, (1990) The synapsins. Annu Rev Cell Biol 6: 433-460.
39. Petersohn D, Schoch S, Brinkmann DR, Thiel G, (1995) The human synapsin II gene promoter. Possible role for the transcription factor zif268/egr-1, polyoma enhancer activator 3, and AP2. J Biol Chem 270: 24361-24369.
40. Rao JS, Rapoport SI, Bosetti F, (2005) Decrease in the AP-2 DNA-binding activity and in the protein expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated with lithium for 6 weeks. Neuropsychopharmacology 30: 2006-2013.
41. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, et al. (2003) Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467-1473.
42. Baldessarini RJ, Tondo L, Faedda GL, Suppes TR, Floris G, et al. (1996) Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 57: 441-448.
43. Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, Walther A, Greil W, (1996) Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 29: 103-107.
44. Muller-Oerlinghausen B, Muser-Causemann B, Volk J, (1992) Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 25: 261-269.
45. Cipriani A, Pretty H, Hawton K, Geddes JR, (2005) Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162: 1805-1819.
46. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, et al. (2006) Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 8: 625-639.